Overview

Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib

Status:
COMPLETED
Trial end date:
2024-04-26
Target enrollment:
Participant gender:
Summary
A study to evaluate the impact of Obicetrapib on the PK levels of Drospirenone and Ethinyl Estradiol (COC) in 30 adult female, healthy volunteers.
Phase:
PHASE1
Details
Lead Sponsor:
NewAmsterdam Pharma
Collaborator:
Novum
Treatments:
drospirenone
Ethinyl Estradiol
Tablets